Janney Montgomery Scott LLC lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 31,368 shares of the company’s stock after selling 1,150 shares during the period. Janney Montgomery Scott LLC owned about 0.11% of Medpace worth $15,063,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the stock. BOKF NA grew its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the period. Valeo Financial Advisors LLC lifted its holdings in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the period. UMB Bank n.a. boosted its position in Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. boosted its position in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC grew its stake in shares of Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after purchasing an additional 26 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.
Medpace Stock Performance
NASDAQ:MEDP opened at $543.57 on Thursday. The stock has a market capitalization of $15.52 billion, a PE ratio of 34.17, a P/E/G ratio of 2.69 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The company has a fifty day moving average of $452.04 and a two-hundred day moving average of $496.20.
Insider Buying and Selling
In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.
Analysts Set New Price Targets
MEDP has been the subject of several recent research reports. Royal Bank Of Canada cut their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Robert W. Baird dropped their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Barclays cut their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $467.08.
Check Out Our Latest Analysis on Medpace
Medpace Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
